The maker of blockbuster appetite-suppressing drugs Mounjaro and Zepbound is seeking to end a regulatory designation that has ...

Eli Lilly & Co.’s stock gained more than 2% on Tuesday after the drugmaker said that tirzepatide, marketed as the diabetes ...

Lilly announced that it will now sell Zepbound in vials, too. And a month's supply of vials with the 2.5 mg doses will cost ...

The makers of Zepbound are offering a massive price cut — if you're willing to purchase and dose your syringes out yourself.

The GLP-1 drug giant’s shares have surged this year. Eli Lilly could keep climbing thanks to strong demand for Mounjaro and ...

Lilly recently announced positive results from a pivotal clinical trial of Mounjaro that could lead to even stronger sales.

Eli Lilly may not be an expensive stock when you consider its long-run growth prospects.

Eli Lilly announced that single-dose vials of the weight-loss drug Zepbound will be sold at a discount price of 50% or more.

The latest results from GLP-1 drugmaker Eli Lilly's clinical trial show that tirzepatide helped people maintain weight loss ...

While Mounjaro has no doubt been a monumental success, Lilly was also working on something else in the background. As Novo ...

Eli Lilly is cutting the cost of certain weight loss drugs, with new single-dose vials costing less than other medications ...

Eli Lilly says it will sell one-dose vials of Zepbound for roughly half the usual monthly list price. The weight loss drug, ...